Elsevier

Fertility and Sterility

Volume 103, Issue 6, June 2015, Pages 1557-1565
Fertility and Sterility

Original article
Xenotransplantation of cryopreserved human ovarian tissue—a systematic review of MII oocyte maturation and discussion of it as a realistic option for restoring fertility after cancer treatment

https://doi.org/10.1016/j.fertnstert.2015.03.001Get rights and content
Under an Elsevier user license
open archive

Objective

To systematically review the reporting of MII (MII) oocyte development after xenotransplantation of human ovarian tissue.

Design

Systematic review in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).

Setting

Not applicable.

Patient(s)

Not applicable.

Intervention(s)

Formation of MII oocytes after xenotransplantation of human ovarian tissue.

Main Outcome Measure(s)

Any outcome reported in Pubmed.

Result(s)

Six publications were identified that report on formation of MII oocytes after xenotransplantation of human ovarian tissue.

Conclusion(s)

Xenografting of human ovarian tissue has proved to be a useful model for examining ovarian function and follicle development in vivo. With human follicles that have matured through xenografting, the possibility of cancer transmission and relapse can also be eliminated, because cancer cells are not able to penetrate the zona pellucida. The reported studies have demonstrated that xenografted ovarian tissue from a range of species, including humans, can produce antral follicles that contain mature (MII) oocytes, and it has been shown that mice oocytes have the potential to give rise to live young. Although some ethical questions remain unresolved, xenotransplantation may be a promising method for restoring fertility. This review furthermore describes the value of xenotransplantation as a tool in reproductive biology and discusses the ethical and potential safety issues regarding ovarian tissue xenotransplantation as a means of recovering fertility.

Key Words

Fertility preservation
ovarian tissue xenotransplantation
ovarian tissue cryopreservation

Cited by (0)

R.D. has nothing to disclose. L.L. has nothing to disclose. T.F. has nothing to disclose. J.K. has nothing to disclose. M.v.W. has nothing to disclose. B.T. has nothing to disclose. H.v.d.V. has nothing to disclose. A.N.S. has nothing to disclose. W.W. has nothing to disclose. I.H. has nothing to disclose. M.W.B. has nothing to disclose.

R.D. and L.L. should be considered similiar in author order.